| P50 | author | Andrew Reay Mackay | Q38322220 |
| P2093 | author name string | Lucia Cappabianca | |
| | Cristina Pellegrini | |
| | Antonietta Rosella Farina | |
| | Luciana Gneo | |
| | Pierdomenico Ruggeri | |
| | Maria-Concetta Fargnoli | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma | Q24307374 |
| | The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain | Q24311495 |
| | Identification of ALK as a major familial neuroblastoma predisposition gene | Q24655923 |
| | Nerve growth factor: role in growth, differentiation and controlling cancer cell development | Q26738684 |
| | Targeting BCL2-Proteins for the Treatment of Solid Tumours | Q26853686 |
| | Targeting Mcl-1 for the therapy of cancer | Q27011870 |
| | The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered | Q27015045 |
| | NTRK gene fusions as novel targets of cancer therapy across multiple tumour types | Q28066821 |
| | Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain | Q28115087 |
| | Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis | Q28140740 |
| | A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 | Q28185858 |
| | TRKing down an old oncogene in a new era of targeted therapy | Q28254287 |
| | A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences | Q28282360 |
| | The trk proto-oncogene encodes a receptor for nerve growth factor | Q28609788 |
| | Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate | Q30234505 |
| | Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia | Q30959617 |
| | TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas | Q31107133 |
| | Kinase fusions are frequent in Spitz tumours and spitzoid melanomas | Q33854847 |
| | Immortalized cells and one oncogene in malignant transformation: old insights on new explanation. | Q33909493 |
| | Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor | Q33947807 |
| | TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor | Q33965019 |
| | Inhibiting NF-κB activation by small molecules as a therapeutic strategy | Q34205025 |
| | Ordered recruitment of dynactin to the microtubule plus-end is required for efficient initiation of retrograde axonal transport | Q34362627 |
| | Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer | Q34501536 |
| | The Warburg Effect: How Does it Benefit Cancer Cells? | Q34509467 |
| | The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD2 expression and activity at the mitochondria, within the context of a tumour stem cell-like phenotype | Q35149468 |
| | TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines. | Q35819484 |
| | Novel transcripts reveal a complex structure of the human TRKA gene and imply the presence of multiple protein isoforms | Q35845700 |
| | Ras trafficking, localization and compartmentalized signalling | Q36043314 |
| | Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. | Q36393034 |
| | Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. | Q36429595 |
| | Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins | Q37152909 |
| | Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. | Q37432550 |
| | Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive metastasis | Q37518299 |
| | New insights into the roles of CHOP-induced apoptosis in ER stress | Q38228726 |
| | Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity. | Q38262750 |
| | Cytosolic proteostasis through importing of misfolded proteins into mitochondria | Q38714671 |
| | TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma. | Q38756797 |
| | TFG clusters COPII-coated transport carriers and promotes early secretory pathway organization | Q38920273 |
| | Cancer Metabolism: Fueling More than Just Growth | Q39061395 |
| | TrkAIII promotes microtubule nucleation and assembly at the centrosome in SH-SY5Y neuroblastoma cells, contributing to an undifferentiated anaplastic phenotype | Q39127901 |
| | Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome | Q39263442 |
| | Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy | Q39325378 |
| | OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing | Q39392716 |
| | Trk activation in the secretory pathway promotes Golgi fragmentation. | Q39745312 |
| | The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability | Q39831330 |
| | DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. | Q39902217 |
| | The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells | Q39948991 |
| | Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells | Q40742617 |
| | Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma | Q40838794 |
| | The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells | Q41831013 |
| | NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis. | Q42041489 |
| | MALARIA AND SOME POLYOMAVIRUSES (SV40, BK, JC, AND MERKEL CELL VIRUSES). | Q42246783 |
| | TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma | Q42249160 |
| | Control of ALK (wild type and mutated forms) phosphorylation: specific role of the phosphatase PTP1B. | Q42435814 |
| | Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome | Q44664720 |
| | Inhibition of nonsense-mediated RNA decay by ER stress | Q45056054 |
| | Establishment of a novel neuroblastoma mouse model | Q46236993 |
| | Phytochemicals and PI3K Inhibitors in Cancer—An Insight | Q47174924 |
| | Mutational analysis of the TrkA gene in prostate cancer | Q47752292 |
| | MicroRNA-509-5p functions as an anti-oncogene in breast cancer via targeting SOD2. | Q47780313 |
| | Chromosomal instability drives metastasis through a cytosolic DNA response | Q50001777 |
| | Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy | Q50070105 |
| | Spontaneous regression of neuroblastoma | Q50156376 |
| | TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation. | Q50321745 |
| | Identification of a DNA Damage-Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers. | Q51100217 |
| | Targeting the PI3K pathway in cancer: are we making headway? | Q52672314 |
| | Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. | Q52692152 |
| | Inhibiting TRK Proteins in Clinical Cancer Therapy. | Q54117764 |
| | Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. | Q54234449 |
| | TrkA glycosylation regulates receptor localization and activity | Q77425782 |
| | TrkAIII expression in the thymus | Q79620602 |
| | Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study | Q79961133 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P921 | main subject | cell surface receptor | Q2476074 |
| | oncoprotein | Q33428353 |
| | genetic variation | Q349856 |
| | membrane protein | Q423042 |
| | enzyme | Q8047 |
| | neoplasm | Q1216998 |
| | neoplasm protein | Q66894191 |
| P304 | page(s) | 119 | |
| P577 | publication date | 2018-06-18 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII. | |
| P478 | volume | 37 | |